Surgery Improve the Prognosis of Colon Mucinous Adenocarcinoma with Liver Metastases: A SEER-Based Study

Jia Huang  
University of South China

Guodong Chen  
University of South China

Huan Liu  
University of South China

Yiwei Zhang  
University of South China

Rong Tang  
University of South China

Qiulin Huang  
University of South China

Kai Fu  
Central China University

Xiuda Peng  
University of South China

Shuai Xiao (xiaoshuai1982@hotmail.com)  
The first affiliated hospital, University of South China  
https://orcid.org/0000-0003-0830-2188

Research article

Keywords: colon carcinoma, mucinous adenocarcinoma, liver metastases, surgery, survival

DOI: https://doi.org/10.21203/rs.3.rs-30252/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background** Mucinous adenocarcinoma (MAC) is the second common pathological type of colon carcinoma (CC). Colon cancer liver metastases (CLM) is common and lethal, complete resection for both of the primary tumor and metastases of CLM would be beneficial. However, there is still no consensus for the role of surgery in MAC of CC with liver metastases (M-CLM).

**Methods** Among 5816 patients who diagnosed with M-CLM or classical adenocarcinoma of CLM (A-CLM) from 2010 to 2013 in the Surveillance, Epidemiology, and End Results (SEER) database were retrieved. The clinicopathological features and overall survival (OS) and cancer-specific survival (CSS) data were compared and analyzed.

**Results** Total of 5816 M-CLM and A-CLM patients were enrolled in this study. Results showed M-CLM group had larger tumor size, more right colon location, high pT and pN stage compared with A-CLM group, as well as more female patients, more examined and positive lymph nodes and a higher proportion of surgery than A-CLM group. The OS and CSS of M-CLM patients accepted any surgery were significantly better than that didn't accept any surgery, but poorer than that of A-CLM patients. Meanwhile, the OS and CSS of M-CLM and A-CLM were comparable when they didn't receive any surgery. Moreover, partial colectomy provided the similar OS and CSS compared with hemicolectomy or greater for M-CLM, and surgery was an independent protective factor for long-term survival of M-CLM.

**Conclusions** M-CLM had distinct clinicopathological characteristics, surgery could improve the long-term survival and act as an independent protective prognostic factor for M-CLM, additionally, partial colectomy might be a better selection for M-CLM from this study.

**Background**

Colon carcinoma (CC) is one of the most common and lethal cancer in the world [1]. A large proportion of CC are dead due to metastasis, more than 20% of patients developed distant metastases at the time of diagnosis[2]. Although the mortality of whole CC is declining, the 5-year survival rate of metastatic CC (mCC) is still miserable and less than 10%[3]. Liver is the most frequent target organ for mCC, and liver metastasis (LM) occurs in up to 25% of stage IV patients [4]. Complete resection of primary tumor and metastatic lesion for some highly-selected resectable colon cancer liver metastasis (CLM) patients is advocated by guidelines and provides better survival than non-surgical treatment, but this part of patients are less than 20% [5–7].

Mucinous adenocarcinoma (MC) is the second most common pathological type after the classical adenocarcinoma (AC) in CC and accounts for 10–15% of all CC patients [8]. According to the WHO, MC is defined as more than 50% of the lesion is composed of extracellular mucin. The molecular characteristics of MC are relative high mutation of BRAF and KRAS, more microsatellite instability high (MSI-H) and CpG island methylator phenohype, and high expression of HATH1 and MUC2 compared with AC[9–11]. The pathogenesis for MC is rarely known, bacterial biofilms, inflammatory bowel diseases (IBD) and
radiotherapy are considered as potential risk factors\cite{12,13}. MC is frequently located in proximal colon and had shorter survival and poorer systemic treatment response compared with AC, thus is always suggested as a poor prognostic predictor for CC\cite{9,14–16}. Therefore, we should pay more attention in clinical management of MC patients.

To date, the prognosis of MC is still highly controversial, mainly because the treatment strategy deviation for metastatic disease\cite{14,17,18}. Although MC has greater propensity for peritoneal dissemination than AC, liver is still the most common metastatic site and accounts for up to 50\% of all metastases\cite{19,20}. Management of these MC CLM (M-CLM) patients has long been controversial. One of important reason is M-CLM is frequently accompanied metastases of other sites, thus a large proportion of M-CLM are traditionally considered unresectable unless emergency circumstances, and many studies suggest that incomplete resection is associated with high recurrence, poorer survival, as well as tumor growth and progression\cite{10,21–24}. However, the relatively poor response to chemotherapy of metastatic MC indicates that surgery may occupy a more important role in treatment of these patients although recurrence is high\cite{14,25,26}. Thus, some study found MC patients with completed resection of primary lesion and M-CLM had poorer survival than AC CLM patients (A-CLM), but other study found surgery for UICC stage IV MC could provide comparable survival as AC patients\cite{17,18,20}. Furthermore, there was still no research to study the role of surgery in M-CLM patients who couldn't perform radical resection. These situation and discrepancy evoke more attention to settle the role of surgery in treatment of M-CLM.

In this study, we have explored the prognosis of M-CLM patients who accepted surgery or not, to both or either of the primary and metastatic lesions. The purpose of this study was to clarify the value of surgery and the prognostic factors for M-CLM patients from the Surveillance, Epidemiology, and End Results program (SEER 18, 1975–2016 varying)( Nitsche et al., 2013;Vigano et al., 2014;Wang et al., 2019 ).

Materials And Methods

Data source

The current study relied on the SEER cancer registry, which is a publicly available and reliable database and could provide follow-up information regarding the vital survival status and death causes. We required cases from 18 SEER registries with the anonymous data and obtained permission to download the research data file from the SEER database, which did not require further informed patient consent.

Patients selection

We accessed the SEER database using the SEER program (www.seer.cancer.gov) and Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 8.3.6, and obtained patients diagnosed with CLM between 2010 and 2013. The study included CLM patients according to the following criteria: 1) the International Classification of Disease for Oncology, Third Edition (ICD-O-3) site codes: cecum, ascending colon,
hepatic flexure, transverse colon, splenic flexure, descending colon and sigmoid colon; 2) ICD-O-3 behavior codes: malignant; 3) diagnostic confirmation: positive histology; 4) ICD-O-3 histology codes: 8140/3: adenocarcinoma, NOS, 8480/3: mucinous adenocarcinoma; 5) American Joint Committee on Cancer (AJCC) 7th edition: M1a; 6) Vital status: alive, dead. The exclusion criteria were in the following: 1) surgery of primary site: blanks; 2) surgery of other regional site and distant site: blanks; 3) site-specific factor 1 (carcinoembryonic antigen, CEA): blanks; 4) age at diagnosis: unknown; 5) Total number of in situ/malignant tumors: unknown; 6) survival months: unknown.

**Outcome measures**

For each patient, the survival outcomes were defined and analyzed: 1) overall survival (OS) was defined as the time from the date of diagnosis to death from any cause; 2) cancer-specific survival (CSS) was defined as the time from the date of diagnosis until cancer-associated death.

**Statistical analysis**

Patient characteristics were summarized in descriptive statistics, and we compared differences in baseline characteristics between the M-CLM groups and A-CLM groups. Continuous data were compared using the one-way ANOVA test, and categorical variables were compared using the chi-square test. The Kaplan-Meier curves were used to estimate OS and CSS, and the log-rank test was used to compare the differences among groups. The prognostic factors associated with OS and CSS were analyzed by univariate and multivariate Cox proportional regression model, and then hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated. All statistical analyses were performed with SPSS Statistical Package version 22.0 (SPSS Inc., Chicago, IL, USA), and P < 0.05 was considered to be statistical significant.

**Results**

**The general demographic and clinicopathological characteristics of M-CLM**

There are total of 7179 patients retrieved from SEER according to the inclusion and exclusion criteria. Then according to SEER Combined Metastasis at DX-liver (2010+) code, a total of 5816 CLM patients enrolled in this study from database of SEER 18 since 2010 to 2015, including 306 cases of M-CLM patients and 5510 cases of A-CLM patients. The demographic and clinicopathological characteristics of these patients were described in Table 1. Results showed that M-CLM patients had the general features of MC such as larger tumor size, more right colon location, high pT and pN stage than that of A-CLM patients (P < 0.05, respectively). In addition, the results also showed M-CLM group had more female patients, more examined and positive lymph nodes and a higher proportion of surgery than A-CLM group (P < 0.05, respectively). Other variables such as race, age, CEA level, primary tumor number and tumor differentiation were comparable between the two groups (P > 0.05, respectively). These results concluded
the primarily different characteristics of M-CLM from A-CLM, which mainly lie in the pathological status of primary lesion.
| Variables                  | A-CLM (5510) | M-CLM (306) | P value |
|----------------------------|--------------|-------------|---------|
| **Race**                   |              |             |         |
| White                      | 4102(74.4%)  | 232(75.8%)  |         |
| Black                      | 935(17.0%)   | 55(18.0%)   |         |
| Others                     | 473(8.6%)    | 19(6.2%)    | 0.501   |
| **Age (years)**            |              |             |         |
| ≤ 60                       | 2023(36.7%)  | 101(33.0%)  |         |
| >60                        | 3487(63.3%)  | 205(67.0%)  | 0.190   |
| **Sex**                    |              |             |         |
| Female                     | 2439(44.3%)  | 153(50.0%)  |         |
| Male                       | 3071(55.7%)  | 153(50.0%)  | 0.049   |
| **CEA**                    |              |             |         |
| Normal                     | 593(10.8%)   | 33(10.8%)   |         |
| Elevated                   | 3244(58.9%)  | 184(60.1%)  |         |
| Unknown                    | 1673(30.4%)  | 89(29.1%)   | 0.890   |
| **Size (cm)**              |              |             |         |
| ≤ 5                        | 2408(43.7%)  | 119(38.9%)  |         |
| >5                         | 1860(33.8%)  | 156(51.0%)  |         |
| Unknown                    | 1242(22.5%)  | 39(10.1%)   | <0.001  |
| **Tumor number**           |              |             |         |
| Solitary                   | 4435(80.5%)  | 248(81.0%)  |         |
| Multiple                   | 1075(19.5%)  | 58(19.0%)   | 0.811   |
| **Location**               |              |             |         |
| Right colon                | 2403(43.6%)  | 181(59.2%)  |         |
| Transverse colon           | 486(8.8%)    | 34(11.1%)   |         |
| Left colon                 | 2621(47.6%)  | 91(29.7%)   | <0.001  |
| **Differentiation**        |              |             |         |
| Variables                  | A-CLM (5510) | M-CLM (306) | P value |
|---------------------------|--------------|-------------|---------|
| Grade I/II                | 3634 (66.0%) | 188 (61.4%) |         |
| Grade III                 | 1172 (21.3%) | 79 (25.8%)  |         |
| Unknown                   | 704 (12.8%)  | 39 (12.7%)  | 0.158   |
| pT stage                  |              |             |         |
| 0–2                       | 562 (10.2%)  | 24 (7.8%)   |         |
| 3–4                       | 3892 (70.6%) | 260 (85.0%) |         |
| Unknown                   | 1054 (19.1%) | 22 (7.2%)   | < 0.001 |
| pN stage                  |              |             |         |
| N0                        | 1668 (30.3%) | 62 (20.3%)  |         |
| N+                        | 3391 (61.5%) | 233 (76.1%) |         |
| Unknown                   | 451 (8.2%)   | 11 (3.6%)   | < 0.001 |
| Examined lymph nodes      | 12.52 ± 11.43| 16.26 ± 10.41| < 0.001|
| Positive lymph nodes      | 4.41 ± 5.04  | 5.37 ± 5.84 | 0.003   |
| Surgery type              |              |             |         |
| No surgery                | 1627 (29.5%) | 34 (11.1%)  |         |
| Any surgery               | 3876 (70.3%) | 272 (88.9%) |         |
| Unknown                   | 7 (0.2%)     | 0 (0%)      | < 0.001 |
| Vital status              |              |             |         |
| Dead                      | 4641 (84.2%) | 272 (88.9%) |         |
| Alive                     | 869 (15.8%)  | 34 (11.1%)  | 0.028   |

**The long-term survival of M-CLM**

We then analyzed the potential survival difference between M-CLM and A-CLM patients and found more patients died in M-CLM group (88.9% vs. 84.2%, P = 0.028, Table 1), thus we further analyzed the difference via Kaplan-Meier curves and Log-rank tests. Results showed the follow-up of the whole study was 0–83 months and the median time was 17.0 months. The OS of M-CLM was comparable with that of A-CLM patients (22.59 ± 1.24 vs. 25.65 ± 0.36 months, P = 0.088, Fig. 1A), the CSS of M-CLM was also similar with that of A-CLM patients (24.33 ± 1.33 vs. 28.19 ± 0.39 months, P = 0.053, Fig. 1B), but the actual values of OS and CSS of M-CLM were lower than that of A-CLM though the difference was not statistically significant. These results indicated that survival of M-CLM is close to A-CLM.
The long-term survival of M-CLM classified by surgery type

Because resection of both primary and metastatic lesions is an important option for survival advantage of CLM, we further explore the potential advantage of different surgery types via survival analyses. Results showed that the entire cohort who accepted the both of the resection had the best OS (41.15 ± 0.96 months, P < 0.001), followed by resection only to primary lesion (26.79 ± 0.47 months) or metastatic lesion (21.44 ± 4.22 months) which had similar OS (P = 0.388), and the patients who didn't perform any surgery had the poorest OS (13.08 ± 0.39 months, P < 0.001) (Fig. 1C). These results were also confirmed in CSS analysis (OS in turn: 43.51 ± 0.99, 29.38 ± 0.51, 22.27 ± 4.42 and 14.63 ± 0.45 months, Fig. 1D). Then, we classified and analyzed the effect of surgery to survival of M-CLM and A-CLM. Results showed M-CLM patients accepted any surgery (no matter both or only resection to primary and metastatic lesions) had significant better OS and CSS than that didn't accept any surgery (P < 0.001, respectively, Fig. 2A-B). The survival analyses in A-CLM group also drew the similar results (P < 0.001, respectively, Fig. 2C-D). These results concluded that surgery held an important position in treatment of M-CLM patients for a better survival, even though resection only to primary or metastatic lesions.

The survival difference of M-CLM and A-CLM stratified by surgery type

We previously found M-CLM had comparable OS and CSS with A-CLM (Fig. 1A-B), since surgery could obtain survival benefit, then we further analyzed the potential survival difference of M-CLM and A-CLM via stratification of surgery types. Results showed that M-CLM patients accepted any surgery had poorer OS (24.02 ± 1.34 vs. 30.84 ± 0.45 months, P < 0.001, Fig. 3A) and CSS (25.74 ± 1.42 vs. 33.54 ± 0.48 months, P < 0.001, Fig. 3B) than that of A-CLM patients. But the OS and CSS had no significant difference between M-CLM and A-CLM patients with none surgery (P = 0.394 and P = 0.404, respectively, Fig. 3C-D). Then we continued to explore the survival difference via stratification of surgery to primary or metastatic lesion. Results showed that in patients with surgery to primary lesion hierarchy, M-CLM had poorer OS and CSS than that of A-CLM patients (P < 0.001, respectively, Fig. 4A-B). The patients with surgery to metastatic lesion hierarchy also showed M-CLM had poorer OS and CSS than that of A-CLM patients (P = 0.044 and P = 0.011, respectively, Fig. 4C-D). These results concluded that although surgery provided survival advantage for entire CLM patients, M-CLM still had the relatively less benefit than A-CLM from surgery.

The effect of surgery option to primary lesion for survival of M-CLM

There are also controversial exist in surgery option selection to primary lesion for CLM to today, thus we further analyzed the surgery option for the survival of M-CLM. There are total of 272 (88.89%, 272/306) M-CLM patients accepted surgery in this study, and partial colectomy (26.10%, 71/272) and hemicolectomy or greater (72.06%, 196/272) were the most common options. Results showed that partial
colectomy had the similar OS compared with hemicolecction or greater (24.63 ± 2.41 vs. 23.65 ± 1.60 months, P = 0.240), but better than no surgery (P < 0.001, respectively, Fig. 5A). The CSS analyses also showed the similar results (Fig. 5B). These results concluded that a more extensive surgery scope of primary lesion would not provide superior survival benefit for M-CLM.

The prognostic risk factors for survival of M-CLM

The survival for M-CLM is poor that we need to explore the potential prognostic risk factor for it. We analyzed the risk factors for OS and CSS of M-CLM by univariate and multivariate Cox proportional hazards regression models in this study. The univariate analyses results showed in Table 2 indicated black race (HR = 0.735, 95% CI: 0.543–0.996), pT3-4 stage (HR = 0.603, 95% CI: 0.392–0.929) and surgery to any or both lesions (Any HR = 0.506, 95% CI: 0.349–0.734; both HR = 0.314, 95% CI: 0.198–0.497) were associated with better OS of M-CLM (Table 2). The black race (HR = 0.691, 95% CI: 0.506–0.944), pT3-4 stage (HR = 0.570, 95% CI: 0.367–0.888) and surgery to any or both lesions (Any HR = 0.497, 95% CI: 0.337–0.735; both HR = 0.330, 95% CI: 0.205–0.531) were also associated with better CSS of M-CLM (Table 2). On the multivariate analysis demonstrated in Table 3, results showed only surgery type (Any HR = 0.478, 95% CI: 0.265–0.862; both HR = 0.316, 95% CI: 0.163–0.609) was independent prognostic factors for better OS; and black race (HR = 0.701, 95% CI: 0.499–0.986), pT3-4 stage (HR = 0.513, 95% CI: 0.306–0.860) and surgery type (Any HR = 0.497, 95% CI: 0.267–0.924; both HR = 0.350, 95% CI: 0.176–0.696) were also associated with better CSS of M-CLM (Table 3). These results concluded once again that the surgery was important for the better long-term survival of M-CLM, no matter surgery to primary lesion or metastatic lesion or both of them.
## Table 2
Univariate analysis of factors associated with overall survival and cancer-specific survival of M-CLM

| Variable      | OS HR(95%CI) | P    | CSS HR(95%CI) | P    |
|---------------|--------------|------|---------------|------|
|               |              |      |               |      |
| **Race**      |              |      |               |      |
| White         | 1            | 0.064| 1             | 0.025|
| Black         | 0.735(0.543–0.996) | 0.047| 0.691(0.506–0.944) | 0.020|
| Others        | 0.562(0.317–0.999) | 0.050| 0.502(0.273–0.924) | 0.027|
| **Age (years)**|              |      |               |      |
| ≤ 60          | 1            |      | 1             |      |
| >60           | 1.128(0.876–1.453) | 0.349| 1.066(0.821–1.385) | 0.629|
| **Sex**       |              |      |               |      |
| Female        | 1            |      | 1             |      |
| Male          | 0.886(0.698–1.124) | 0.319| 0.888(0.693–1.139) | 0.350|
| **CEA**       |              |      |               |      |
| Normal        | 1            | 0.429| 1             | 0.281|
| Elevated      | 1.195(0.800–1.784) | 0.385| 1.379(0.890–2.138) | 0.151|
| Unknown       | 1.324(0.861–2.035) | 0.202| 1.456(0.911–2.328) | 0.117|
| **Size (cm)** |              |      |               |      |
| ≤ 5           | 1            | 0.153| 1             | 0.192|
| >5            | 1.189(0.922–1.533) | 0.182| 1.157(0.888–1.508) | 0.281|
| Unknown       | 1.455(0.964–2.197) | 0.074| 1.463 (0.955–2.241) | 0.081|
| **Tumor number** |         |      |               |      |
| Solitary      | 1            |      | 1             |      |
| Multiple      | 1.244(0.921–1.681) | 0.155| 1.073(0.772–1.492) | 0.675|
| Variable          | OS          |            | CSS         |            |
|-------------------|-------------|------------|-------------|------------|
|                   | HR(95%CI)   | P          | HR(95%CI)   | P          |
| **Location**      |             |            |             |            |
| Right colon       | 1           | 0.996      | 1           | 0.939      |
| Transverse colon  | 1.003(0.675–1.492) | 0.987 | 1.038(0.687–1.567) | 0.859      |
| Left colon        | 0.989(0.759–1.290) | 0.937 | 1.049(0.797–1.380) | 0.734      |
| **Differentiation** |           |            |             |            |
| Grade 1/2         | 1           | 0.528      | 1           | 0.547      |
| Grade 3/4         | 1.000(0.754–1.326) | 0.998 | 1.013(0.755–1.358) | 0.933      |
| Unknown           | 1.221(0.855–1.745) | 0.271 | 1.229(0.847–1.783) | 0.278      |
| **pT stage**      |             |            |             |            |
| 0–2               | 1           | 0.004      | 1           | 0.002      |
| 3–4               | 0.603(0.392–0.929) | 0.022 | 0.570(0.367–0.888) | 0.013      |
| Unknown           | 1.104(0.610–1.997) | 0.745 | 1.105(0.602–2.028) | 0.747      |
| **pN stage**      |             |            |             |            |
| N0                | 1           | 0.117      | 1           | 0.192      |
| N+                | 0.844(0.629–1.134) | 0.261 | 0.892(0.652–1.219) | 0.473      |
| Unknown           | 1.502(0.787–2.867) | 0.217 | 1.570(0.796–3.097) | 0.193      |
| **Surgery type**  |             |            |             |            |
| No surgery        | 1           | < 0.001    | 1           | < 0.001    |
| Surgery to primary or metastatic lesion | 0.506(0.349–0.734) | < 0.001 | 0.497(0.337–0.735) | < 0.001    |
| Both              | 0.314(0.198–0.497) | < 0.001 | 0.330(0.205–0.531) | < 0.001    |
| Others            | 1.080(0.259–4.509) | 0.916 | 1.201(0.286–5.037) | 0.802      |
Table 3  
Multivariate analysis of factors associated with OS and CSS of M-CLM

| Variable                  | OS            | CSS          |
|---------------------------|---------------|--------------|
|                           | OS HR(95%CI)  | CSS HR(95%CI)|
|                           | P             | P            |
| Race                      |               |              |
| White                     | NS            | 1            |
| Black                     | 0.701(0.499–0.986) | 0.041        |
| Others                    | 0.362(0.183–0.715) | 0.003        |
| Surgery type              |               |              |
| No surgery                | 1             | 1            |
| Surgery to primary or metastatic lesion | 0.478(0.265–0.862) | 0.014        |
| Both                      | 0.316(0.163–0.609) | 0.001        |
| Others                    | 1.080(0.182–4.159) | 0.862        |
| pT stage                  |               |              |
| 0–2                       | NS            | 1            |
| 3–4                       | 0.513(0.306–0.860) | 0.011        |
| Unknown                   | 0.785(0.365–1.688) | 0.535        |

**Abbreviations:** NS: no significant difference.

**Discussion**

Surgery for colon cancer with liver metastasis is a critical and controversial issue and continues to this day. Though most researchers believe that completed resection of both of primary and metastatic lesions would provide a survival advantage than systemic therapy, the mainly dispute is whether palliative resection of part of lesions is benefit for patients, especially resection only to primary colon cancer or liver metastasis[27]. What’s more, systemic chemotherapy, molecular targeted therapy, immunotherapy, portal vein or hepatic artery embolization and radiofrequency ablation play a gradually more important role in mCC treatment, which might provide a potentially longer survival and downstaging of tumor[5, 23, 27, 28]. This situation causes that surgery occupies a gradual weakening trend in CLM treatment, and many
studies support the view that surgery would bring more trauma, stress and immunosuppression for CLM patients and probably prompt tumor growth, recurrence and wouldn’t bring survival benefit [24, 29–33]. However, there are also some studies stated clearly that resection primary colon cancer or liver metastasis associated with improved survival, and suggested a more aggressive method for the incurable diseases[23, 34–36].

This dilemma is amplifying in M-CLM, because MC is always characterized by peritoneal implant and metastases at multiple sites which increase difficulty of completed resection[18, 20, 37]. What’s more, most studies consider MC histology is an adverse prognostic for survival, as well as in M-CLM, which aggravate the concern of surgery[10, 15, 17]. However, the relatively low response to systemic therapy of MC compared with AC draws a dilemma in treatment of M-CLM, which evokes the rethinking of surgery in M-CLM[15, 37]. In this study, we found M-CLM also had general features as MC that such as more right colon location, larger tumor size and advanced pT and pN stage compared with A-CLM, but the long-term survival of overall M-CLM and A-CLM were comparable. These overturn the traditional knowledge of MC had poorer survival than AC, especially diagnosed at a high stage (III/IV)[14, 38]. However, our findings were consistent with some recent studies that survival of overall MC was poorer than AC, but stage IV MC had similar survival as AC[17, 39]. These findings indicated that though M-CLM had specific clinicopathological features, the long-term survival is comparable with A-CLM.

Another important finding of the present study was no matter surgery to both primary and metastatic lesions or only to any of the lesions of CLM patients, the survival were better than that of no surgery. This conclusion was also verified by stratification of M-CLM and A-CLM, and confirmed the importance of surgery for survival benefit of M-CLM, which was also supported by some former studies[34, 36]. We also explored the potential independent risk factors for survival of M-CLM by univariate and multivariate analyses. Results also showed surgery played a dominated role for favor OS and CSS, no matter surgery to both primary and metastatic lesions or any of the lesions. These results once again highlighted the importance of surgery for better prognosis of M-CLM. However, we further found M-CLM had the poorer OS and CSS than A-CLM in hierarchy of patients accepted any surgery. This finding was different from studies about surgery to stage IV MC[17, 40], but similar with a recent study from Italy that M-CLM associated with worse OS and disease-free survival[18]. One potential explanation for the discrepancy is the studies of stage IV MC didn’t stratify the sub-classification of M-CLM, since M-CLM always accompanied other sites and/or peritoneal metastasis which would deteriorate the prognosis[15, 18, 37]. Another possible reason is that adjuvant chemotherapy is an important option for postoperative treatment for M-CLM though this study didn’t include the information. However, M-CLM always resistant to systemic chemotherapy which might also lead to relatively poor survival after surgery[15, 41].

Surgery type of primary lesion is also a most debated issue for M-CLM, the most often types are partial colectomy and hemicolectomy or greater. Some surgeons tend to choose the partial colectomy cause M-CLM is a terminal stage and surgery couldn’t improve survival even bring poor prognosis[29–31]. However, others thought extended resection such as hemicolectomy or greater would provide a probability for subsequent curable resection or sensitivity for systemic chemotherapy, which might
prolong survival[32, 35, 36]. In the present study, we found partial colectomy provided a similar OS and CSS as hemicolectomy or greater, this finding strengthened the concept of minimizing the trauma for advanced cancer. There are some potential speculation for this, it is most likely that the extended resection would have broken immune system and homeostasis, and sometimes even promoted tumor growth and metastasis[24]. Thus, a more appropriate surgery option should be selected carefully when an operation decision is made for M-CLM.

This study has found the important role of surgery for better survival of M-CLM. However, there were also some limitation in the study. First and foremost, we couldn't obtain the pre- and/or post-operative systemic therapy information which would weaken the scientific and academic rigour. Secondly, this study couldn't recognize which patients received primary and metastatic lesions resection synchronously or subsequently. Third, because our study enrolled patients with pathological confirmation and detailed staging information in the SEER database, which would exclude many metastatic disease patients without pathological diagnosis. Thus, more excellent designed retrospective and prospective multi-center studies are needed in the future to overcome these weaknesses.

Despite these limitations, this study concluded M-CLM had distinct clinicopathological characteristics from A-CLM, and highlighted surgery could improve the long-term survival and was the independent favorable prognostic factor for survival even though surgery to any lesion of M-CLM, in addition, partial colectomy might be a better selection for M-CLM from this study. In conclusion, our study updated the understanding of surgery for MAC of metastatic colon carcinoma.

List Of Abbreviations

mucinous adenocarcinoma (MAC); colon carcinoma (CC); colon cancer liver metastases (CLM); MAC of CC with liver metastases (M-CLM); End Results (SEER); overall survival (OS); cancer-specific survival (CSS); adenocarcinoma (AC); bowel diseases (IBD); carcinoembryonic antigen (CEA); hazard ratios (HRs); confidence intervals (CIs);

Declarations

Ethics approval and consent to participate

The data obtained permission to download the research data file from the SEER database, which did not require further informed ethics approval and consent to participate.

Consent for publication

Not applicable.

Availability of data and material

All data generated or analysed during this study are included in this published article.
Competing interests

The authors declare that they have no competing interests.

Funding

This work was funded by the National Natural Sciences Foundation of China (81702949, 31900561), the Natural Sciences Foundation of Hunan Province (2018JJ3851), the Key Project of Health Commission of Hunan Province (20201919) and the Huxiang Talent Aggregation Project from Hunan Provincial Science and Technology Department (2018RS3027).

Authors’ contributions

JH, GDC, KF, SX conceived the study and wrote the manuscript. JH, GDC, HL, RT, YWZ, QLH, KF, XDP and SX conducted the experiments and contributed to the analysis of data. KF, XDP and SX revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2020;70:7–30.
2. Catalano V, Loupakis F, Graziano F, Bisonni R, Torresi U, Vincenzi B, et al. Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Ann Oncol. 2012;23:135–41.
3. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester R, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.
4. Feo L, Polcino M, Nash GM. Resection of the Primary Tumor in Stage IV Colorectal Cancer. Surg Clin North Am. 2017;97:657–69.
5. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–422.
6. Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Primers. 2015;1:150–65.
7. Costi R, Leonardi F, Zanoni D, Violi V, Roncoroni L. Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist. World J Gastroenterol. 2014;20:7602–21.
8. Vigano L, Russolillo N, Ferrero A, De Rosa G, Ferreri E, Forchino F, et al. Resection of liver metastases from colorectal mucinous adenocarcinoma: is this a different disease? Results of a case-control study. Ann Surg. 2014;260:878–84. discussion 884-5.
9. Reynolds IS, Furney SJ, Kay EW, McNamara DA, Prehn J, Burke JP. Meta-analysis of the molecular associations of mucinous colorectal cancer. Br J Surg. 2019;106:682–91.

10. Mekenkamp LJ, Heesterbeek KJ, Koopman M, Tol J, Teerenstra S, Venderbosch S, et al. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012;48:501–9.

11. Park ET, Oh HK, Gum JJ, Crawley SC, Kakar S, Engel J, et al. HATH1 expression in mucinous cancers of the colorectum and related lesions. Clin Cancer Res. 2006;12:5403–10.

12. Li S, Peppelenbosch MP, Smits R. Bacterial biofilms as a potential contributor to mucinous colorectal cancer formation. Biochim Biophys Acta Rev Cancer. 2019;1872:74–9.

13. Hugen N, van Beek JJ, de Wilt JH, Nagtegaal ID. Insight into mucinous colorectal carcinoma: clues from etiology. Ann Surg Oncol. 2014;21:2963–70.

14. Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011;12:1071–80.

15. Hugen N, Brown G, Glynne-Jones R, de Wilt JH, Nagtegaal ID. Advances in the care of patients with mucinous colorectal cancer. Nat Rev Clin Oncol. 2016;13:361–9.

16. Rosati G, Galli F, Cantore M, Bergamo F, Banzi M, Zampino MG, et al. Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis. Oncologist 2020.

17. Nitsche U, Zimmermann A, Spath C, Muller T, Maak M, Schuster T, et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg. 2013;258:775–82.

18. Vigano L, Russolillo N, Ferrero A, De Rosa G, Ferreri E, Forchino F, et al. Resection of liver metastases from colorectal mucinous adenocarcinoma: is this a different disease? Results of a case-control study. Ann Surg. 2014;260:878–84.

19. Hugen N, van de Velde CJ, de Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014;25:651–7.

20. Wang J, Li S, Liu Y, Zhang C, Li H, Lai B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med 2019.

21. Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, et al. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell. 2019;179:561–77.

22. Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15:91–103.

23. Mahmoud N, Bullard DK. Metastasectomy for stage IV colorectal cancer. Dis Colon Rectum. 2010;53:1080–92.

24. Govaert KM, Jongen J, Kranenburg O, Borel RI. Surgery-induced tumor growth in (metastatic) colorectal cancer. Surg Oncol. 2017;26:535–43.

25. Verhulst J, Ferdinande L, Demetter P, Ceelen W. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis. J Clin Pathol. 2012;65:381–8.
26. Fonseca GM, Herman P, Faraj SF, Kruger J, Coelho FF, Jeismann VB, et al. Pathological factors and prognosis of resected liver metastases of colorectal carcinoma: implications and proposal for a pathological reporting protocol. Histopathology. 2018;72:377–90.

27. de Ridder J, van der Stok EP, Mekenkamp LJ, Wiering B, Koopman M, Punt C, et al. Management of liver metastases in colorectal cancer patients: A retrospective case-control study of systemic therapy versus liver resection. Eur J Cancer. 2016;59:13–21.

28. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018;16:359–69.

29. Feo L, Polcino M, Nash GM. Resection of the Primary Tumor in Stage IV Colorectal Cancer: When Is It Necessary? Surg Clin North Am. 2017;97:657–69.

30. Yun JA, Huh JW, Park YA, Cho YB, Yun SH, Kim HC, et al. The role of palliative resection for asymptomatic primary tumor in patients with unresectable stage IV colorectal cancer. Dis Colon Rectum. 2014;57:1049–58.

31. Wong SF, Wong HL, Field KM, Kosmider S, Tie J, Wong R, et al. Primary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent. Clin Colorectal Cancer. 2016;15:e125-32.

32. Shao YC, Chang YY, Lin JK, Lin CC, Wang HS, Yang SH, et al. Neoadjuvant chemotherapy can improve outcome of colorectal cancer patients with unresectable metastasis. Int J Colorectal Dis. 2013;28:1359–65.

33. Damjanov N, Weiss J, Haller DG. Resection of the Primary Colorectal Cancer Is Not Necessary in Nonobstructed Patients with Metastatic Disease. Oncologist. 2009;14:963–9.

34. Frankel TL, D'Angelica MI. Hepatic resection for colorectal metastases. J Surg Oncol. 2014;109:2–7.

35. Takada T, Tsutsumi S, Takahashi R, Ohsone K, Tatsuki H, Suto T, et al. Control of primary lesions using resection or radiotherapy can improve the prognosis of metastatic colorectal cancer patients. J Surg Oncol. 2016;114:75–9.

36. de Mestier L, Neuzillet C, Pozet A, Desot E, Deguelte-Lardiere S, Volet J, et al. Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience. Eur J Surg Oncol. 2014;40:685–91.

37. Luo C, Cen S, Ding G, Wu W. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun (Lond). 2019;39:13.

38. Hyngstrom JR, Hu CY, Xing Y, You YN, Feig BW, Skibber JM, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012;19:2814–21.

39. Kang H, O'Connell JB, Maggard MA, Sack J, Ko CY. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 2005;48:1161–8.

40. Jimi S, Hotokezaka M, Ikeda T, Uchiyama S, Hidaka H, Maehara N, et al. Clinicopathological features, postoperative survival and prognostic variables for cancer-related survival in patients with mucinous colorectal carcinoma. Surg Today. 2015;45:329–34.
Catalano V, Loupakis F, Graziano F, Torresi U, Bisonni R, Mari DF, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and or irinotecan-based chemotherapy. Br J Cancer. 2009;100:881–7.

Figures
Figure 1

Long-term survival of CLM. A-B: The survival curves showed that the overall M-CLM group had similar overall survival (OS) (A) and cancer-specific survival (CSS) (B) with the A-CLM group; C-D: The survival curves showed that the CLM group who accepted the resection both to primary lesion and metastatic lesion had the best OS (C) and CSS (D), followed by the resection only to primary lesion or metastatic lesion which had similar OS and CSS, and the patients who didn’t receive any surgery had the poorest OS and CSS.
Figure 2

Long-term survival of CLM grouped by surgery and stratified by histology. A-B: The survival curves showed that the M-CLM patients who received any surgery had better OS (A) and CSS (B) than those didn't accept any surgery; C-D: The survival curves showed A-CLM patients who received any surgery also had better OS (C) and CSS (D) than those didn't accept any surgery.
Figure 3

The stratified analysis for long-term survival of CLM according to surgery type. A-B: The survival curves showed that the M-CLM group received any surgery had poorer OS (A) and CSS (B) than the A-CLM group; C-D: the survival curves showed M-CLM and A-CLM groups had similar OS (C) and CSS (D) when didn’t perform any surgery.
Figure 4

The stratified analysis for long-term survival of CLM according to resection of tumor lesions. A-B: The survival curves showed that the M-CLM group had poorer OS (A) and CSS (B) than the A-CLM group in patients with surgery to primary lesion; C-D: The survival curves showed that the M-CLM group had poorer OS (C) and CSS (D) than the A-CLM group in patients with surgery to metastatic lesion.
Figure 5

Long-term survival of M-CLM according to surgery type of primary lesion resection. A: The survival curves showed that the M-CLM patients who accepted partial colectomy had the similar OS compared with those group who accepted hemicolecctiony or greater, but better than those didn’t accept surgery. B: The CSS analysis also showed the similar results.